FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141284503> ?p ?o ?g. }

• W2141284503 endingPage "728" @default.
• W2141284503 startingPage "722" @default.
• W2141284503 abstract "Clofarabine is a nucleoside analog with activity in myeloid malignancies. Experience in myelodysplastic syndrome (MDS) is limited.The goal of this study was to evaluate the activity and safety of 2 different doses (15 mg/m(2) vs 30 mg/m(2) daily × 5 days) of intravenous clofarabine in patients with higher-risk MDS. Fifty-eight patients with a median age of 68 years (range, 25-89) including 15 patients (28%) with secondary MDS and 35 patients (60%) who received prior DNA methyltransferase (DNMT) inhibitors were adaptively randomized between the 2 dose cohorts.The overall response rate (ORR; based on a modification of International Working Group criteria) was 36% including 26% with complete remission (CR) (ORR, 41% at 15 mg/m(2) and 29% at 30 mg/m(2)). Responses were lower in patients who failed DNMT inhibitors (ORR, 17%; CR rate, 14%). The 8-week mortality rate was 19%. Median survival was 7.4 months for all patients, 13.4 months for responders, and 21.7 months for complete responders. Some adverse events, particularly hepatic and renal, were more severe (grade >2) in patients randomized to 30 mg/m(2) of clofarabine. Myelosuppression and infectious complications were frequent.Both the lower and higher doses of clofarabine have comparable clinical activity, but the lower dose appeared less toxic. If these results are confirmed, lower doses of clofarabine, possibly in alternative schedules, should be pursued." @default.
• W2141284503 created "2016-06-24" @default.
• W2141284503 creator A5000750846 @default.
• W2141284503 creator A5015140142 @default.
• W2141284503 creator A5024454882 @default.
• W2141284503 creator A5036115627 @default.
• W2141284503 creator A5046097970 @default.
• W2141284503 creator A5049385583 @default.
• W2141284503 creator A5055045706 @default.
• W2141284503 creator A5061026876 @default.
• W2141284503 creator A5077963154 @default.
• W2141284503 creator A5084290698 @default.
• W2141284503 creator A5090435894 @default.
• W2141284503 date "2011-07-12" @default.
• W2141284503 modified "2023-10-15" @default.
• W2141284503 title "A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome" @default.
• W2141284503 cites W187238933 @default.
• W2141284503 cites W1963779075 @default.
• W2141284503 cites W2008860560 @default.
• W2141284503 cites W2024950851 @default.
• W2141284503 cites W2079671946 @default.
• W2141284503 cites W2081279521 @default.
• W2141284503 cites W2096638244 @default.
• W2141284503 cites W2102776788 @default.
• W2141284503 cites W2106584820 @default.
• W2141284503 cites W2107029748 @default.
• W2141284503 cites W2114009381 @default.
• W2141284503 cites W2114492363 @default.
• W2141284503 cites W2116171965 @default.
• W2141284503 cites W2126572589 @default.
• W2141284503 cites W2129510594 @default.
• W2141284503 cites W2135801126 @default.
• W2141284503 cites W2140291353 @default.
• W2141284503 cites W2569893980 @default.
• W2141284503 doi "https://doi.org/10.1002/cncr.26327" @default.
• W2141284503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4180241" @default.
• W2141284503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21751197" @default.
• W2141284503 hasPublicationYear "2011" @default.
• W2141284503 type Work @default.
• W2141284503 sameAs 2141284503 @default.
• W2141284503 citedByCount "26" @default.
• W2141284503 countsByYear W21412845032012 @default.
• W2141284503 countsByYear W21412845032013 @default.
• W2141284503 countsByYear W21412845032014 @default.
• W2141284503 countsByYear W21412845032015 @default.
• W2141284503 countsByYear W21412845032016 @default.
• W2141284503 countsByYear W21412845032017 @default.
• W2141284503 countsByYear W21412845032018 @default.
• W2141284503 countsByYear W21412845032019 @default.
• W2141284503 crossrefType "journal-article" @default.
• W2141284503 hasAuthorship W2141284503A5000750846 @default.
• W2141284503 hasAuthorship W2141284503A5015140142 @default.
• W2141284503 hasAuthorship W2141284503A5024454882 @default.
• W2141284503 hasAuthorship W2141284503A5036115627 @default.
• W2141284503 hasAuthorship W2141284503A5046097970 @default.
• W2141284503 hasAuthorship W2141284503A5049385583 @default.
• W2141284503 hasAuthorship W2141284503A5055045706 @default.
• W2141284503 hasAuthorship W2141284503A5061026876 @default.
• W2141284503 hasAuthorship W2141284503A5077963154 @default.
• W2141284503 hasAuthorship W2141284503A5084290698 @default.
• W2141284503 hasAuthorship W2141284503A5090435894 @default.
• W2141284503 hasBestOaLocation W21412845032 @default.
• W2141284503 hasConcept C126322002 @default.
• W2141284503 hasConcept C141071460 @default.
• W2141284503 hasConcept C168563851 @default.
• W2141284503 hasConcept C185592680 @default.
• W2141284503 hasConcept C197934379 @default.
• W2141284503 hasConcept C2776543447 @default.
• W2141284503 hasConcept C2777198975 @default.
• W2141284503 hasConcept C2777333352 @default.
• W2141284503 hasConcept C2778041864 @default.
• W2141284503 hasConcept C2778729363 @default.
• W2141284503 hasConcept C2780007613 @default.
• W2141284503 hasConcept C2780817109 @default.
• W2141284503 hasConcept C71240020 @default.
• W2141284503 hasConcept C71924100 @default.
• W2141284503 hasConcept C90924648 @default.
• W2141284503 hasConceptScore W2141284503C126322002 @default.
• W2141284503 hasConceptScore W2141284503C141071460 @default.
• W2141284503 hasConceptScore W2141284503C168563851 @default.
• W2141284503 hasConceptScore W2141284503C185592680 @default.
• W2141284503 hasConceptScore W2141284503C197934379 @default.
• W2141284503 hasConceptScore W2141284503C2776543447 @default.
• W2141284503 hasConceptScore W2141284503C2777198975 @default.
• W2141284503 hasConceptScore W2141284503C2777333352 @default.
• W2141284503 hasConceptScore W2141284503C2778041864 @default.
• W2141284503 hasConceptScore W2141284503C2778729363 @default.
• W2141284503 hasConceptScore W2141284503C2780007613 @default.
• W2141284503 hasConceptScore W2141284503C2780817109 @default.
• W2141284503 hasConceptScore W2141284503C71240020 @default.
• W2141284503 hasConceptScore W2141284503C71924100 @default.
• W2141284503 hasConceptScore W2141284503C90924648 @default.
• W2141284503 hasIssue "3" @default.
• W2141284503 hasLocation W21412845031 @default.
• W2141284503 hasLocation W21412845032 @default.
• W2141284503 hasLocation W21412845033 @default.
• W2141284503 hasLocation W21412845034 @default.
• W2141284503 hasOpenAccess W2141284503 @default.

• next